Jurmay

Jurmay is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of next-generation small molecule targeted therapies. The company focuses on high-value targets in oncology and immunology, utilizing its internal drug discovery platform to create potent and selective inhibitors. Its lead candidate, JM-001, is a brain-penetrant RET inhibitor currently being evaluated in clinical trials for patients with RET-altered cancers, such as non-small cell lung cancer and thyroid cancer. Jurmay's pipeline also includes programs targeting TRK, KRAS G12C, and SHP2, aiming to address resistance mechanisms and improve outcomes in precision oncology. The company is supported by a strong network of life science investors, including Qiming Venture Partners and Lilly Asia Ventures.